Cargando…

Immunological consequences of microbiome-based therapeutics

The complex network of microscopic organisms living on and within humans, collectively referred to as the microbiome, produce wide array of biologically active molecules that shape our health. Disruption of the microbiome is associated with susceptibility to a range of diseases such as cancer, diabe...

Descripción completa

Detalles Bibliográficos
Autores principales: Alam, Md Zahidul, Maslanka, Jeffrey R., Abt, Michael C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878555/
https://www.ncbi.nlm.nih.gov/pubmed/36713364
http://dx.doi.org/10.3389/fimmu.2022.1046472
_version_ 1784878510919122944
author Alam, Md Zahidul
Maslanka, Jeffrey R.
Abt, Michael C.
author_facet Alam, Md Zahidul
Maslanka, Jeffrey R.
Abt, Michael C.
author_sort Alam, Md Zahidul
collection PubMed
description The complex network of microscopic organisms living on and within humans, collectively referred to as the microbiome, produce wide array of biologically active molecules that shape our health. Disruption of the microbiome is associated with susceptibility to a range of diseases such as cancer, diabetes, allergy, obesity, and infection. A new series of next-generation microbiome-based therapies are being developed to treat these diseases by transplanting bacteria or bacterial-derived byproducts into a diseased individual to reset the recipient’s microbiome and restore health. Microbiome transplantation therapy is still in its early stages of being a routine treatment option and, with a few notable exceptions, has had limited success in clinical trials. In this review, we highlight the successes and challenges of implementing these therapies to treat disease with a focus on interactions between the immune system and microbiome-based therapeutics. The immune activation status of the microbiome transplant recipient prior to transplantation has an important role in supporting bacterial engraftment. Following engraftment, microbiome transplant derived signals can modulate immune function to ameliorate disease. As novel microbiome-based therapeutics are developed, consideration of how the transplants will interact with the immune system will be a key factor in determining whether the microbiome-based transplant elicits its intended therapeutic effect.
format Online
Article
Text
id pubmed-9878555
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98785552023-01-27 Immunological consequences of microbiome-based therapeutics Alam, Md Zahidul Maslanka, Jeffrey R. Abt, Michael C. Front Immunol Immunology The complex network of microscopic organisms living on and within humans, collectively referred to as the microbiome, produce wide array of biologically active molecules that shape our health. Disruption of the microbiome is associated with susceptibility to a range of diseases such as cancer, diabetes, allergy, obesity, and infection. A new series of next-generation microbiome-based therapies are being developed to treat these diseases by transplanting bacteria or bacterial-derived byproducts into a diseased individual to reset the recipient’s microbiome and restore health. Microbiome transplantation therapy is still in its early stages of being a routine treatment option and, with a few notable exceptions, has had limited success in clinical trials. In this review, we highlight the successes and challenges of implementing these therapies to treat disease with a focus on interactions between the immune system and microbiome-based therapeutics. The immune activation status of the microbiome transplant recipient prior to transplantation has an important role in supporting bacterial engraftment. Following engraftment, microbiome transplant derived signals can modulate immune function to ameliorate disease. As novel microbiome-based therapeutics are developed, consideration of how the transplants will interact with the immune system will be a key factor in determining whether the microbiome-based transplant elicits its intended therapeutic effect. Frontiers Media S.A. 2023-01-12 /pmc/articles/PMC9878555/ /pubmed/36713364 http://dx.doi.org/10.3389/fimmu.2022.1046472 Text en Copyright © 2023 Alam, Maslanka and Abt https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Alam, Md Zahidul
Maslanka, Jeffrey R.
Abt, Michael C.
Immunological consequences of microbiome-based therapeutics
title Immunological consequences of microbiome-based therapeutics
title_full Immunological consequences of microbiome-based therapeutics
title_fullStr Immunological consequences of microbiome-based therapeutics
title_full_unstemmed Immunological consequences of microbiome-based therapeutics
title_short Immunological consequences of microbiome-based therapeutics
title_sort immunological consequences of microbiome-based therapeutics
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878555/
https://www.ncbi.nlm.nih.gov/pubmed/36713364
http://dx.doi.org/10.3389/fimmu.2022.1046472
work_keys_str_mv AT alammdzahidul immunologicalconsequencesofmicrobiomebasedtherapeutics
AT maslankajeffreyr immunologicalconsequencesofmicrobiomebasedtherapeutics
AT abtmichaelc immunologicalconsequencesofmicrobiomebasedtherapeutics